Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 20/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 16/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 16/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2833931 | 1.00 | CHRM3 (0.62) | CHRM3CHRM2CHRM1 | |
| SCHEMBL5007141 | 0.82 | CHRM3 (0.54) | CHRM3CHRM2CHRM1 | |
| SCHEMBL5007158 | 0.81 | CHRM3 (0.53) | CHRM3CHRM2CHRM1 | |
| SCHEMBL2816413 | 0.79 | CHRM3 (0.79) | CHRM3CHRM2CHRM1 | |
| SCHEMBL2816273 | 0.79 | CHRM3 (0.65) | CHRM3CHRM2CHRM1 | |
| SCHEMBL5007005 | 0.79 | CHRM3 (0.66) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL6080131 | 0.79 | CHRM3 (0.79) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL5490833 | 0.78 | CHRM3 (0.65) | CHRM3CHRM2CHRM1 | |
| SCHEMBL5003450 | 0.78 | CHRM3 (0.55) | CHRM3CHRM2CHRM1 | |
| SCHEMBL5006311 | 0.77 | CHRM3 (0.64) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776879-B2 | Quinuclidine carbamate derivatives and their use as M3 antagonists | ALMIRALL, S.A. (ES) | 2010-08-17 | — | — | US | disclosed |
| US-20090054480-A1 | NOVEL QUINUCLIDINE CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | LABORATORIOS ALMIRALL S.A. | 2009-02-26 | — | — | US | disclosed |
| US-20090005412-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | LABORATORIOS ALMIRALL S.A. | 2009-01-01 | — | — | US | disclosed |
| US-7435742-B2 | Quinuclidine derivatives and pharmaceutical compositions containing the same | LABORATORIOS ALMIRALL S.A. (ES) | 2008-10-14 | — | — | US | disclosed |
| US-20080021060-A1 | Quinuclidine carbamate derivatives and their use as M3 antagonists | ALMIRALL PRODESFARMA AG | 2008-01-24 | — | — | US | disclosed |
| US-7312231-B2 | Quinuclidine carbamate derivatives and their use as M3 antagonists | ALMIRALL PRODESFARMA AG (CH) | 2007-12-25 | — | — | US | disclosed |
| US-7208501-B2 | Quinuclidine carbamate derivatives and their use as M3 antagonists | ALMIRALL PRODESFARMA AG (CH) | 2007-04-24 | — | — | US | disclosed |
| EP-1345937-B1 | QUINUCLIDINE CARBAMATE DERIVATIVES AND THEIR USE AS M3 ANTAGONISTS | ALMIRALL PRODESFARMA AG (CH) | 2005-09-28 | — | — | EP | disclosed |
| EP-1515968-A2 | QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Almirall Prodesfarma AG (CH) | 2005-03-23 | — | — | EP | disclosed |
| US-20040266816-A1 | Quinuclidine carbamate derivatives and their use as M3 antagonists | ALMIRALL, S.A. (ES) | 2004-12-30 | — | — | US | disclosed |
| US-20040242629-A1 | Quinuclidine carbamate derivatives and their use as M3 antagonists | LABORATORIOS ALMIRALL S.A. (ES) | 2004-12-02 | — | — | US | disclosed |
| WO-2004000840-A2 | QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA AG (CH) | 2003-12-31 | — | — | WO | disclosed |
| EP-1345937-A1 | QUINUCLIDINE CARBAMATE DERIVATIVES AND THEIR USE AS M3 ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002051841-A1 | QUINUCLIDINE CARBAMATE DERIVATIVES AND THEIR USE AS M3 ANTAGONISTS | ALMIRALL PRODESFARMA AG (CH) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005412-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRM2, CHRM1 | CHRM3 1/4885CHRM2 2/4885CHRM1 3/4885 |
| US-20080021060-A1 | Quinuclidine carbamate derivatives and their use as M3 antagonists | CHRM3, CHRM2, CHRM1 | CHRM3 1/4885CHRM2 2/4885CHRM1 3/4885 |
| US-20040242629-A1 | Quinuclidine carbamate derivatives and their use as M3 antagonists | CHRM3, CHRM2, CHRM1 | CHRM3 1/4885CHRM2 2/4885CHRM1 3/4885 |
| US-20040266816-A1 | Quinuclidine carbamate derivatives and their use as M3 antagonists | CHRM3, CHRM1, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 2/4885 |
| US-20090054480-A1 | NOVEL QUINUCLIDINE CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRM2, CHRM1 | CHRM3 1/4885CHRM2 2/4885CHRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.